| [1] |
Wudhikarn K, Palomba ML, Pennisi M, et al. Infection during the first year in patients treated with CD 19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J, 2020, 10(8): 79. doi:10.1038/s41408-020-00346-7.
doi: 10.1038/s41408-020-00346-7
pmid: 32759935
|
| [2] |
中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2020年修订). 中华内科杂志, 2020, 59(5):341-346. doi:10.3760/cma.j.cn112138-20200304-00179.
doi: 10.3760/cma.j.cn112138-20200304-00179
|
| [3] |
June CH, Sadelain M. Chimeric Antigen Receptor Therapy. N Engl J Med, 2018, 379(1): 64-73. doi:10.1056/NEJMra1706169.
doi: 10.1056/NEJMra1706169
URL
|
| [4] |
陈文明. 复发难治性多发性骨髓瘤治疗解读及嵌合抗原受体T细胞对治疗模式的挑战. 中华内科杂志, 2020, 59(5):338-340. doi:10.3760/cma.j.cn112138-20200224-00120.
doi: 10.3760/cma.j.cn112138-20200224-00120
|
| [5] |
肖希斌, 李萍, 梁爱斌, 等. 《嵌合抗原受体T细胞疗法的免疫相关不良事件管理:ASCO指南》解读. 实用肿瘤杂志, 2022, 37(1):1-7. doi:10.13267/j.cnki.syzlzz.2022.001.
doi: 10.13267/j.cnki.syzlzz.2022.001
|
| [6] |
Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet, 2020, 396(10254): 839-852. doi:10.1016/S0140-6736(20)31366-0.
doi: S0140-6736(20)31366-0
pmid: 32888407
|
| [7] |
Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol, 2019, 20(1): 31-42. doi:10.1016/S1470-2045(18)30864-7.
doi: 10.1016/S1470-2045(18)30864-7
|
| [8] |
Logue JM, Zucchetti E, Bachmeier CA, et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica, 2021, 106(4): 978-986. doi:10.3324/haematol.2019.238634.
doi: 10.3324/haematol.2019.238634
pmid: 32327504
|
| [9] |
Wittmann Dayagi T, Sherman G, Bielorai B, et al. Chara-cteristics and risk factors of infections following CD28-based CD 19 CAR-T cells. Leuk Lymphoma, 2021, 62(7): 1692-1701. doi:10.1080/10428194.2021.1881506.
doi: 10.1080/10428194.2021.1881506
URL
|
| [10] |
Bupha-Intr O, Haeusler G, Chee L, et al. CAR-T cell therapy and infection: a review. Expert Rev Anti Infect Ther, 2021, 19(6): 749-758. doi:10.1080/14787210.2021.1855143.
doi: 10.1080/14787210.2021.1855143
URL
|
| [11] |
Stewart AG, Henden AS. Infectious complications of CAR T-cell therapy: a clinical update. Ther Adv Infect Dis, 2021, 8: 20499361211036773. doi:10.1177/20499361211036773.
doi: 10.1177/20499361211036773
|
| [12] |
徐丽楠. 浅谈肺结核病防控健康教育体系的建立. 中国继续医学教育, 2015(10):10-11. doi:10.3969/j.issn.1674-9308.2015.10.008.
doi: 10.3969/j.issn.1674-9308.2015.10.008
|
| [13] |
黄河, 徐开林, 周剑峰. CAR-T细胞治疗免疫学. 北京: 人民卫生出版社, 2021: 219-223.
|
京公网安备11010202007215号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可
